Defence Therapeutics Inc.: Defence Therapeutics Accum Variants in Vitro Study Increases the Potency of T-Deruxtecan ADC by 5-Fold on Breast Cancer
Vancouver, British Columbia--(Newsfile Corp. - October 13, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF ("Defence" or the "Company"), a biotechnology company working on cancer
EtelÀuomen LÀi United Kingdom British Columbia Daiichi Sankyo Sebastien Plouffe Defence Therapeutics Inc
Source: finanznachrichten.de